SCHEMBL3490201

SCHEMBL3490201

COc1cccc(N2C(=O)N(Cc3ccccc3)c3cc(Cl)cc(N4CCN(C)CC4)c3S2(=O)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.47
HCRTR2 O43614 1/20 0.47
HTR1A P08908 1/20 0.45
HTR7 P34969 1/20 0.45
HTR6 P50406 1/20 0.45
MAPT P10636 9/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
LMNA P02545 1/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KCNH2 Q12809 2/20 0.41
CMA1 P23946 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
ABCB1 P08183 2/20 0.40
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489218 0.92 HTT (0.52) HCRTR1HCRTR2MAPTGAAHTT
SCHEMBL3489612 0.91 HCRTR1 (0.46) HCRTR1HCRTR2HTR1AHTR7HTR6
SCHEMBL3488683 0.91 MAPT (0.48) HCRTR1HCRTR2MAPTGAAHTT
SCHEMBL3490153 0.87 CMA1 (0.46) HTR1AHTR7HTR6MAPTGAA
SCHEMBL3489534 0.87 HCRTR1 (0.52) HCRTR1HCRTR2MAPTGAAHTT
SCHEMBL3490797 0.85 HCRTR1 (0.48) HCRTR1HCRTR2HTR1AHTR7HTR6
SCHEMBL3489300 0.83 MEN1 (0.42) HTR1AHTR7HTR6MAPTGAA
SCHEMBL3490715 0.83 HTT (0.51) HCRTR1HCRTR2HTR1AHTR7MAPT
SCHEMBL3489592 0.81 MAPT (0.49) HTR1AMAPTGAALMNATP53
SCHEMBL3488417 0.81 HCRTR1 (0.43) HCRTR1HCRTR2HTR1AHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HCRTR1 131/4885HCRTR2 138/4885HTR1A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.